Can Diffusion Microstructural Imaging Provide Insights Into Long Covid Beyond Conventional MRI?
In a recent interview, Alexander Rau, M.D., discussed emerging research, presented at the recent RSNA conference, that shows the capability of diffusion microstructural imaging to differentiate subtle shifts in microstructural gray matter associated with common symptomatology of long Covid.
Long Covid may affect up to 41 percent of non-hospitalized adults who have had COVID-19, according to the Centers for Disease Control and Prevention (CDC).
However, diffusion microstructural imaging, a novel magnetic resonance imaging (MRI) technique, may provide improved insight into associations between microstructural changes in the brain and common Long Covid effects such as neurocognitive deficits, fatigue, and olfactory dysfunction, according to new research presented at the recent Radiological Society of North America (RSNA) conference.
In a recent interview, Alexander Rau, M.D., one of the lead authors of the study, discussed key findings from the prospective research that compared 89 patients with long Covid, 38 patients who had a COVID-19 infection but didn’t have long Covid, and 46 patients with no history of COVID-19.
By utilizing diffusion microstructural imaging, Dr. Rau and his colleagues discovered patterns of microstructural gray matter alterations that differed between those with long Covid and those who didn’t have long Covid after having a COVID-19 infection, particularly in basal brain structures.
“There is an impact of COVID-19 on the brain’s microstructure that we could measure with advanced diffusion imaging that was undetectable on conventional (MRI) imaging,” noted Dr. Rau, a resident in the Departments of Neuroradiology and Diagnostic and Interventional Radiology at University Hospital Freiburg in Freiburg, Germany. “Those alterations were associated with post-COVID condition associated symptoms such as fatigue, impaired olfaction, and cognitive decline. Thus, there is evidence that those alterations contribute to the pathophysiology of the post-COVID condition.”
(Editor’s note: For related content, see “MRI Study: People with Past Hospitalization for COVID-19 Have Nearly Triple the Risk of Multiorgan Abnormalities,” “New Meta-Analysis Details Most Common Brain MRI Findings with COVID-19” and “Seven Takeaways from New Consensus Recommendations for Cardiac MRI Assessment of COVID-19.”)
For more insights from Dr. Rau, watch the video below.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
FDA Issues Expanded Pediatric Approval of MRI Contrast Agent for Lung Ventilation Assessment
June 2nd 2025Previously approved for MRI lung ventilation evaluation in adults and children 12 and older, the hyperpolarized contrast agent Xenoview can now be utilized for pediatric patients six years and older.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Breast MRI and Background Parenchymal Enhancement: What a Meta-Analysis Reveals
May 29th 2025Moderate or marked background parenchymal enhancement (BPE) reduces the sensitivity and specificity of MRI for breast cancer detection by more than 10 percent in comparison to scans with minimal or mild BPE, according to a new meta-analysis.
